U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

PSI-6130

MORE DETAILS

  05J68784G1

Status:
Investigational
Source:
NCT01628094: Phase 2 Interventional Completed Hepatitis C, Chronic
(2012)
Source URL:
https://clinicaltrials.gov/ct2/show/NCT01628094
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Hepatitis C virus NS5B RNA-dependent RNA polymerase
14
Conditions:
Hepatitis C
42
Mericitabine is a specific inhibitor of hepatitis C virus (HCV) replication that target NS5B polymerase. Mericitabine, a prodrug, is hydrolyzed in vivo to produce PSI-6130. It had been studied in phase II clinical trials for the treatment of chronic hepatitis C. However, while it showed a good safety profile in clinical trials, it was not sufficiently effective to be used as a standalone agent.

MERICITABINE

MORE DETAILS

  TA63JX8X52

Status:
Investigational
Source:
NCT01628094: Phase 2 Interventional Completed Hepatitis C, Chronic
(2012)
Source URL:
https://clinicaltrials.gov/ct2/show/NCT01628094
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Hepatitis C virus NS5B RNA-dependent RNA polymerase
14
Conditions:
Hepatitis C
42
Mericitabine is a specific inhibitor of hepatitis C virus (HCV) replication that target NS5B polymerase. Mericitabine, a prodrug, is hydrolyzed in vivo to produce PSI-6130. It had been studied in phase II clinical trials for the treatment of chronic hepatitis C. However, while it showed a good safety profile in clinical trials, it was not sufficiently effective to be used as a standalone agent.
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966